Navigation Links
Gen-Probe Reports Financial Results for the Second Quarter of 2011

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) today reported financial results for the second quarter of 2011, with total revenues of $135.9 million and non-GAAP earnings per share (EPS) of $0.51.  

"Gen-Probe posted record sales of APTIMA women's health products in the second quarter of 2011, while supply chain fluctuations caused blood screening revenue to decline compared to strong sales a year ago," said Carl Hull, the Company's president and chief executive officer.  "In addition, we are off to a good start with the first of several new product launches in the United States, and with our PANTHER® introduction in Europe."

Key financial results for the second quarter of 2011 were ($ in millions, except EPS):Non-GAAPGAAP2011




ChangeProduct sales





--Total revenues





-2%Operating profit





-13%Net income










-21%Revenue DetailIn the second quarter of 2011, clinical diagnostics product sales grew by 18% compared to the prior year period.  This increase was driven primarily by domestic and international growth of the APTIMA Combo 2® assay for detecting Chlamydia and gonorrhea, and by the inclusion of GTI product sales, which were not part of Gen-Probe in the prior year period.  Foreign currency fluctuations increased clinical diagnostics sales by an estimated $1.3 million compared to the prior year period.

In blood screening, sales declined compared to the second quarter of 2010, as expected, due to lower shipments of assays and insal

204,786195,820Accumulated other comprehensive (loss) income

(7,471)678Retained earnings

672,497626,876Total stockholders' equity

869,817823,379Total liabilities and stockholders' equity

$  1,219,740$  1,167,797Gen-Probe IncorporatedConsolidated Statements of Income – GAAP(In thousands, except per share data)

(Unaudited)Three Months EndedSix Months EndedJune 30,June 30,2011201020112010Revenues:Product sales

$132,921$132,734$271,033$  263,303Collaborative research revenue

1,6174,1415,1857,405Royalty and license revenue

1,3601,7742,7183,360Total revenues

135,898138,649278,936274,068Operating expenses:Cost of product sales (excluding acquisition-related intangible amortization)

39,43144,31181,37486,972Acquisition-related intangible amortization

2,7292,1995,5344,415Research and development

27,71327,10456,67656,785Marketing and sales

17,51015,82434,03230,605General and administrative

18,70315,01836,85629,697Total operating expenses

106,086104,456214,472208,474Income from operations

29,81234,19364,46465,594Other income (expense):Investment and interest income

2,9373,2693,6727,167Interest expense

(497)(549)(1,000)(1,095)Gain on contingent consideration

—4,337—6,082Other income (expense), net

1,315(190)1,492(349)Total other income, net

3,7556,8674,16411,805Income before income tax

33,56741,06068,62877,399Income tax expense

11,22312,95023,00725,096Net income

$  22,344$  28,110$  45,621$  52,303Net income per share:Basic

$  0.47$  0.57$  0.95$  1.06Diluted

$  0.45$  0.57$  0.93$  1.05Weighted average shares outstanding:Basic


49,33849,36649,19649,549Gen-Probe IncorporatedConsolidated Statements of Income – Non-GAAP Reconciliations(In thousands, except per share data)

(Unaudited)Three Months EndedThree Months EndedJune 30, 2011June 30, 2010Non—GAAPAdjustmentsGAAPNon—GAAPAdjustmentsGAAPRevenues:Product sales


$  —


$  —

$132,734Collaborative research revenue



4,141Royalty and license revenue



1,774Total revenues



138,649Operating expenses:Cost of product sales (excluding acquisition-related intangible amortization)





44,311Acquisition-related intangible amortization




2,199Research and development




27,104Marketing and sales




15,824General and administrative





15,018Total operating expenses





104,456Income from operations





34,193Other income (expense):Investment and interest income



3,269Interest expense



(549)Gain on contingent consideration



4,337Other income (expense), net



(190)Total other income, net




6,867Income before income tax





41,060Income tax expense





12,950Net income

$  25,295


$  22,344$  25,961


$  28,110Net income per share:Basic

$  0.53

$  (0.06)

$  0.47$  0.53

$  0.04

$  0.57Diluted

$  0.51

$  (0.06)

$  0.45$  0.52

$  0.05

$  0.57Weighted average shares outstanding:Basic






49,366Gen-Probe IncorporatedConsolidated Statements of Income – Non-GAAP Reconciliations(In thousands, except per share data)

(Unaudited)Six Months EndedSix Months EndedJune 30, 2011June 30, 2010Non-GAAPAdjustmentsGAAPNon-GAAPAdjustmentsGAAPRevenues:Product sales


$  —


$  —

$263,303Collaborative research revenue



7,405Royalty and license revenue



3,360Total revenues



274,068Operating expenses:Cost of product sales (excluding acquisition-related intangible amortization)





86,972Acquisition-related intangible amortization




4,415Research and development




56,785Marketing and sales




30,605General and administrative





29,697Total operating expenses





208,474Income from operations





65,594Other income (expense):Investment and interest income



7,167Interest expense



(1,095)Gain on contingent consideration



6,082Other income (expense), net



(349)Total other income, net




11,805Income before income tax





77,399Income tax expense





25,096Net income



$  45,621$  49,932


$  52,303Net income per share:Basic

$  1.08

$  (0.13)

$  0.95$  1.01

$  0.05

$  1.06Diluted

$  1.05

$  (0.12)

$  0.93$  1.00

$  0.05

$  1.05Weighted average shares outstanding:Basic






49,549Gen-Probe IncorporatedConsolidated Statements of Cash Flows – GAAP(In thousands)

(Unaudited)Six Months EndedJune 30, 20112010Operating activities:Net income

$  45,621$  52,303Adjustments to reconcile net income to net cash provided by
operating activities:Depreciation and amortization

22,88622,628Amortization of premiums on investments, net of
accretion of discounts

5,2094,523Stock-based compensation

12,85912,338Excess tax benefit from employee stock-based compensation

(3,916)(919)Deferred revenue

12(1,241)Deferred income tax

(1,632)(1,930)Gain on contingent consideration

—(6,082)Loss on disposal of property and equipment

207143Changes in assets and liabilities:Trade and other accounts receivable


(540)2,998Prepaid expenses

(4,205)1,907Other current assets

44918Other long-term assets

(453)390Accounts payable

(3,417)(7,082)Accrued salaries and employee benefits

(3,999)(4,336)Other accrued expenses

342(1,086)Income tax payable

11,4378,530Other long-term liabilities

769(684)Net cash provided by operating activities

85,51481,824Investing activities:Proceeds from sales and maturities of marketable securities

223,439281,958Purchases of marketable securities

(162,258)(168,395)Purchases of property, plant and equipment

(23,245)(14,567)Purchases of capitalized software

(2,547)(1,457)Purchases of intangible assets, including licenses and manufacturing access fees

(4,424)(1,865)Cash paid for investment in Pacific Biosciences

—(50,000)Cash paid for investment in Roka Bioscience


(348)(1,967)Net cash provided by investing activities

26,63743,707Financing activities:Repurchase and retirement of common stock

(47,972)(52,299)Proceeds from issuance of common stock and employee stock purchase plan

40,72720,062Repurchase and retirement of restricted stock for payment of taxes

(363)(43)Excess tax benefit from employee stock-based compensation

3,916919Borrowings, net

8,000—Net cash provided by (used in) financing activities

4,308(31,361)Effect of exchange rate changes on cash and cash equivalents

570(1,864)Net increase in cash and cash equivalents

117,02992,306Cash and cash equivalents at the beginning of period

59,69082,616Cash and cash equivalents at the end of period

$  176,719$  174,922 truments to Novartis, the Company's blood screening partner.  Although total blood screening assay revenue for the joint business increased compared to the prior year period, Gen-Probe's assay shipments to Novartis decreased by nearly $6 million, instrument shipments declined by nearly $5 million, and additional supply chain fluctuations reduced sales by approximately $3 million.

"We believe the decrease in blood screening sales resulted mainly from reductions in our partner's inventory levels and lower instrument revenues," said Hull.  "The underlying fundamentals of our blood screening business remain healthy, evidenced by the solid donation volumes, market share and profitability we experienced in the second quarter."

The percentage decline in blood screening sales in the second quarter of 2011 was magnified when compared to strong sales in the prior year period, which were more than $5 million higher than in any other quarter last year.  Finally, foreign currency fluctuations increased blood screening sales by an estimated $1.1 million compared to the prior year period.  

Sales of research products and services in the second quarter of 2011 were $2.3 million, down 28% compared to the prior year period due to continued market weakness affecting contract research organizations.  Foreign currency fluctuations increased sales of research products and services by an estimated $0.2 million compared to the prior year period.

Second quarter product sales were ($ in millions):Three Months Ended June 30,Change2011


Constant CurrencyClinical Diagnostics



+17%Blood Screening



-24%Research Products  and Services



-34%Total Product Sales



-2%Collaborative research revenues in the second quarter of 2011 were $1.6 million, compared to $4.1 million in the prior year period, a decrease of 61% that resulted primarily from an expected decrease in funding from Novartis associated with the development of the fully automated PANTHER instrument for the blood screening market.

Royalty and license revenues in the second quarter of 2011 were $1.4 million, compared to $1.8 million in the prior year period.  

GAAP Income Statement DetailsGross margin on product sales was 70.3% in the second quarter of 2011, compared to 66.6% in the prior year period.  This increase resulted mainly from a favorable product sales mix, namely higher sales of APTIMA products and lower sales of instrumentation to Novartis.  

Acquisition-related amortization expenses were $2.7 million in the second quarter of 2011, compared to $2.2 million in the prior year period, an increase of 23% that resulted mainly from the acquisition of GTI in December of 2010.

Research and development (R&D) expenses were $27.7 million in the second quarter of 2011, compared to $27.1 million in the prior year period, an increase of 2% that resulted primarily from the addition of GTI's R&D programs.  

Marketing and sales expenses were $17.5 million in the second quarter of 2011, compared to $15.8 million in the prior year period, an increase of 11% that resulted primarily from the addition of GTI's cost structure, and ongoing European commercial expansion.  

General and administrative (G&A) expenses were $18.7 million in the second quarter of 2011, compared to $15.0 million in the prior year period, an increase of 25% that resulted from the addition of GTI's cost structure, increased legal expenses, and higher stock-based compensation.  

Total other income, net, was $3.8 million in the second quarter of 2011, compared to $6.9 million in the prior year period, a decrease of 45% that resulted primarily from a non-cash gain in the prior year period related to a change in the fair value of contingent consideration in connection with the acquisition of PRODESSE.  

Income tax expense was $11.2 million in the second quarter of 2011, leading to a tax rate of 33%.  

Non-GAAP Income Statement DetailsExcluding $0.1 million of acquisition-related depreciation expense, gross margin on product sales was 70.4% in the second quarter of 2011, compared to 66.7% in the prior year period.

Excluding transaction-related and restructuring costs, G&A expenses were $17.3 million in the second quarter of 2011, compared to $14.3 million in the prior year period.

Income tax expense was $12.5 million in the second quarter of 2011, leading to a tax rate of 33%.

Cash Flows and Balance SheetIn the second quarter of 2011, Gen-Probe generated net cash of $45.4 million from operating activities, more than double GAAP net income of $22.3 million.  The Company spent $12.5 million on property, plant and equipment in the quarter, leading to free cash flow of $32.9 million.  

Gen-Probe continues to have a strong balance sheet.  As of June 30, 2011, the Company had $529.4 million of cash, cash equivalents and marketable securities, and $248 million of short-term debt.  The Company pays interest on this debt at a rate 0.6% above the one-month London Interbank Offered Rate (LIBOR), which was recently below 0.2%.  

Updated 2011 Financial Guidance"We are tightening our 2011 revenue guidance based on our first-half performance," said Herm Rosenman, the Company's senior vice president, finance, and chief financial officer.  "We also are adjusting our EPS guidance based on the higher share count and stock compensation expense resulting from the recent increase in our share price, the effects of which are partially offset by higher gross margins."  Gen-Probe's updated 2011 financial guidance is provided below:Current











(GAAP)Total revenues

$575 to $590 million

$570 to $595 million

$575 to $590 million

$570 to $595 millionProduct gross margins

69% to 70%

68% to 69.5%

69% to 70%

68% to 69.5%Acquisition-related amortization and other transaction expense



$15 million

$13 to $14 millionOperating margin

27% to 29%

27% to 29%

24.5% to 26.5%

25% to 27%Tax rate

32% to 33%

32% to 33%

32% to 33%

32% to 33%Diluted shares

49 million

48 to 49 million

49 million

48 to 49 millionEPS

$2.28 to $2.37

$2.28 to $2.40

$2.06 to $2.15

$2.06 to $2.20Notes on PresentationIn this news release, all per share amounts are calculated on a fully diluted basis.  Some totals may not foot due to rounding.  Certain prior year amounts have been reclassified to conform to the current year presentation.  Estimates of "constant currency" results exclude currency fluctuations associated with revenue from GTI, which was not part of Gen-Probe in the second quarter of 2010.

About Non-GAAP Financial MeasuresGen-Probe's management believes that non-GAAP financial measures provide meaningful supplemental information regarding the Company's performance by excluding certain expenses that may not be indicative of core business results.  To supplement the Company's financial results for the second quarter of 2011 and its updated 2011 financial guidance, in each case presented in accordance with GAAP, Gen-Probe uses the following financial measures defined as non-GAAP by the SEC: non-GAAP net income, non-GAAP gross margin, non-GAAP marketing and sales expenses, non-GAAP G&A expenses, non-GAAP operating profit, non-GAAP income tax rate, and non-GAAP EPS.  Gen-Probe's management does not, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP.  Gen-Probe believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing Gen-Probe's performance and when planning, forecasting and analyzing future periods.  These non-GAAP financial measures also facilitate management's internal comparisons to Gen-Probe's historical performance and our competitors' operating results.  Gen-Probe believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making.  Further, our reconciliations of non-GAAP to GAAP operating results, which are included on the attached tables, are presented in the format of consolidated statements of income solely to assist a reader in understanding the impact of the various adjustments to our GAAP operating results, individually and in the aggregate, and are not intended to place any undue prominence on our non-GAAP operating results.

Webcast Conference CallA live webcast of Gen-Probe's second quarter 2011 conference call for investors can be accessed at beginning at 4:30 p.m. Eastern Time today.  The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours.  Call 866-415-2341 (domestic) or 203-369-0686 (international).  

About Gen-ProbeGen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to

TrademarksAPTIMA, APTIMA COMBO 2, PANTHER and PRODESSE are trademarks of Gen-Probe.  All other trademarks are the property of their owners.

Caution Regarding Forward-Looking StatementsAny statements in this news release about our expectations, beliefs, plans, objectives, assumptions or future events or performance, including those under the heading "Updated 2011 Financial Guidance," are not historical facts and are forward-looking statements.  These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  For example, statements concerning Gen-Probe's financial condition, possible or expected results of operations, the development and commercialization of new products, regulatory approvals, future milestones, growth opportunities, market trends, and plans of management are all forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied.  Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2011 financial targets, (ii) the risk that we may not integrate acquisitions, such as Tepnel, PRODESSE and GTI, successfully, (iii) the possibility that the market for the sale of our new products, such as our PANTHER instrument system and PROGENSA PCA3, APTIMA HPV and APTIMA trichomonas assays, may not develop as expected, (iv) the enhancement of existing products and the development of new products may not proceed as planned, (v) the risk that investigational products, including those now in US clinical trials, may not be approved by regulatory authorities or become commercially available in the time frame we anticipate, or at all, (vi) the risk that we may not be able to compete effectively, (vii) the risk that we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, (viii) our dependence on Novartis and other third parties for the distribution of some of our products, (ix) our dependence on a small number of customers, contract manufacturers and single source suppliers of raw materials, (x) changes in third-party reimbursement policies regarding our products could adversely affect sales, (xi) changes in government regulation or tax policy affecting our diagnostic products could harm our sales, increase our development costs or increase our taxes, (xii) the risk that our intellectual property may be infringed by third parties or invalidated, and (xiii) our involvement in patent and other intellectual property and commercial litigation could be expensive and could divert management's attention.  This list includes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC, including our most recent annual report on Form 10-K and all subsequent periodic reports.  We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Michael Watts
Vice president, investor relations and
corporate communications

Gen-Probe IncorporatedConsolidated Balance Sheets – GAAP(In thousands, except share and per share data)June 30,December 31,20112010(Unaudited)AssetsCurrent assets:Cash and cash equivalents

$  176,719$  59,690Marketable securities

212,499170,648Trade accounts receivable, net of allowance for doubtful accounts of $414 and $355 at June 30, 2011 and December 31, 2010, respectively

52,74254,739Accounts receivable — other


70,66666,416Deferred income tax

13,16913,634Prepaid income tax

2932,993Prepaid expenses

15,93611,672Other current assets

5,1245,148Total current assets

550,717390,433Marketable securities, net of current portion

140,227259,317Property, plant and equipment, net

169,262160,863Capitalized software, net

15,02013,981Patents, net


150,830150,308Purchased intangibles, net

116,006120,270License, manufacturing access fees and other assets, net

65,56360,175Total assets

$  1,219,740$1,167,797Liabilities and stockholders' equityCurrent liabilities:Accounts payable

$  11,358$  14,614Accrued salaries and employee benefits

22,94726,825Other accrued expenses

13,93913,935Income tax payable

5,470634Short-term borrowings

248,000240,000Deferred income tax

97-Deferred revenue

1,3871,166Total current liabilities

303,198297,174Non-current income tax payable

9,0418,315Deferred income tax

27,95529,775Deferred revenue, net of current portion

2,2692,500Other long-term liabilities

7,4606,654Commitments and contingenciesStockholders' equity:Preferred stock, $0.0001 par value per share; 20,000,000 shares authorized, none issued and outstanding

——Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 48,170,514 and 47,966,156 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively

55Additional paid-in capit

SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
2. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
3. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
4. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
5. Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
6. Promising Clinical Data on Gen-Probes APTIMA(R) HPV Test Presented at Major European Medical Meeting
7. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2008 Earnings Conference Call
8. Eric Lai Joins Gen-Probe as Senior Vice President, Research and Development
9. Gen-Probe Borrows $170 Million Under New Line of Credit
10. Gen-Probe to Webcast Two Upcoming Investor Presentations
11. Gen-Probe Completes Acquisition of Tepnel Life Sciences
Post Your Comments:
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... ... Talon Innovations, a provider of Precision Machined Products and Assemblies ... one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the category ... was recognized as a nominee for this competitive award. , The “Best in ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
(Date:10/7/2015)... -- ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV ) ("ContraVir" or ... and commercialization of targeted antiviral therapies, today announced the ... of its common stock and warrants to purchase up ... a fixed combined price to the public of $3.00. ... issued separately.  The warrants will be exercisable for a ...
Breaking Biology Technology:
... comes to consumer goods, America is addicted to them. And ... prices, Wal-Mart is the biggest low-price outlet going. We like ... it. , ,The company that many Americans hate to love ... groups have successfully derailed its growth plans in certain parts ...
... BioSurfaces, Inc. , a privately held life sciences ... , the world's largest monoclonal antibody manufacturer, to ... with GenTel's new custom multiplex immunoassay development service. ... System will be used to develop new custom ...
... 3M Community Giving , the charitable arm of ... Mechanical and Industrial Engineering Building Project. , ,The gift will ... in 3M multimedia projectors for the building. In recognition of ... The 3M Auditorium. , ,The project will update the Mechanical ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 ... This New Study Reveals Selling Opportunities and Revenue ... What,s the future of biologics, especially new drug ... You will stay ahead with exclusive market data ... can explore trends, developments, results, opportunities and sales ...
(Date:9/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that the ... of Modern, will feature the Wocket® smart wallet for ... . Touch Of Modern is an ... products to its 7.2 million members. Customers are affluent, ...
(Date:9/8/2015)... Sept. 8, 2015  Affectiva, global leader in ... a Service, a new data solution, and version ... on Affectiva,s highly accurate and patented science, these ... slated to transform industries such as market research, ... customer experience, online education, HR, automotive, robotics, healthcare ...
Breaking Biology News(10 mins):
... potential for an outbreak of the phenomenon commonly called ... spring and summer, according to researchers with the Woods ... (NCSU). This advisory is based in part ... Alexandrium fundyense the algae notorious ...
... international team of researchers from China and the United ... Early Cretaceous rocks in the southern part of the ... Jiayuguan, Gansu Province, China. Two of their discoveries represent ... in technical publications published on-line in the Proceedings ...
... in French . Scientists at the ... Japan along with researchers from McGill University and other ... are controlled in mammals. Three years of intensive research by ... publication of several milestone scientific papers in Nature Genetics ...
Cached Biology News:
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: